Compare Regeneron Pharmaceuticals Inc (REGN) vs Zeta Global Holdings Corp (ZETA) Price & Performance

Regeneron Pharmaceuticals (REGN) trades at $739.28, down 0.38% on the day, with a bearish technical signal and neutral oscillators. The company shows strong fundamentals with a P/E of 18.3, net income margin of 27.86%, and consistent earnings beats in recent quarters. Recent news highlights a major $8 billion immunology alliance expansion with Sanofi, including a $1 billion upfront payment, reinforcing its pipeline strength and long-term growth prospects.

The outlook remains positive driven by robust profitability, strategic collaborations, and a bullish analyst consensus with a $849.84 price target. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. Institutional sentiment is strong with no sell ratings, supporting a favorable risk-reward profile for investors seeking exposure to biopharmaceutical innovation.

ZETA trades at $33.74, showing strong technical momentum with a bullish moving average signal and trading near resistance at $34. The company demonstrates solid revenue growth with Q2 2026 revenue reaching $1.6B and has beaten earnings estimates for three consecutive quarters. Recent expansion into the UK market and AI platform adoption are driving investor optimism, though negative net margins and high valuation multiples warrant caution.

ZETA presents a growth opportunity with strong analyst support (75% buy ratings) and AI-driven business expansion, but faces execution risks from negative profitability and elevated valuation metrics. The stock's current price above the $32.40 consensus target suggests near-term consolidation potential amid ongoing business transformation efforts.